May 2, 2024

Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Double-blind studies have demonstrated that motor complications in Parkinson's disease (PD) can be reduced with continuous delivery of levodopa. The DopaFuse system is a novel, intraoral micropump that attaches to a retainer and uses a propellant to deliver levodopa/carbidopa (LD/CD) continuously into the mouth.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Olanow et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6bbe0b6db64358763cba2 https://doi.org/https://doi.org/10.1002/mds.29824

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial2024 · 73 citations
2Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating Scale2011 · 384 citations
3Dopamine as A Possible Neurotransmitter in Gastric Relaxation1976 · 175 citations
4The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults2011 · 5,039 citations
5METABOLISM AND ABSORPTION OF <scp>l</scp>‐3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSON'S DISEASE1971 · 81 citations

Preguntar a la IA

Me gusta

Guardar